Rocket Lab (NASDAQ: RKLB) trades at $64.26, sitting roughly 57% below its 52-week high of $151 after a string of setbacks rattled investor confidence.
A Stage 1 tank test failure pushed the debut of the company’s Neutron medium-lift rocket to Q4 2026, with management acknowledging the year-end launch window is narrowing considerably.
Despite that pressure, Stifel analyst Erik Rasmussen maintains a Street-high price target of $150, implying the stock more than doubles from its current level.
The broader Wall Street consensus from 18 analysts sits at an average target of $111, still representing implied upside of roughly 72.7% from current trading levels.
Rasmussen’s bull thesis rests on three pillars: Neutron commercialization expanding Rocket Lab into mega-constellation and defense payloads, an expansion in higher-margin Space Systems revenue, and continued Space Force and SDA wins as a reliable non-SpaceX prime.
Rocket Lab ended Q2 with a record $2.36 billion backlog, up 137% year over year, and management flagged more than $1 billion in new contracts signed already in Q3.
The defense pipeline adds further weight to the bull case, with the company booking the $397 million Flatellite contract for the Space Force SB-AMPI program, the $816 million SDA Tracking Layer Tranche 3 award, and work on the Golden Dome Space Based Interceptor program with Raytheon.
The FY2027 Department of War budget request allocates $71.2 billion to the U.S. Space Force, a substantial growth vector for space prime contractors like Rocket Lab.
Q2 revenue of $234.07 million grew 62% year over year and beat consensus, though GAAP EPS of -0.08 missed expectations after $8.58 million in acquisition-related costs emerged.
Management has also announced a deal to acquire Iridium Communications, positioning Rocket Lab as a self-launching, integrated space and communications operator.
The company raised $1.53 billion through an at-the-market equity program in the first half of the year, intensifying dilution concerns among shareholders already rattled by the Neutron delay.
Shares are down 14.11% over the past month while the S&P 500 was essentially flat at 0.05%, underscoring the company-specific nature of the selling pressure.
Of 18 analysts covering RKLB, 3 rate the stock Strong Buy, 11 Buy, and 4 Hold, with none carrying a Sell rating, reflecting broadly constructive sentiment on Wall Street.
Forward revenue estimates show $958 million for FY2026 rising to $1.36 billion for FY2027, though both years carry negative average EPS estimates reflecting ongoing investment spending.
Peers across the space sector are also trading well below their consensus targets, with AST SpaceMobile (NASDAQ: ASTS) near $62.31 against a $79.61 average target representing roughly 28% upside.
Intuitive Machines (NASDAQ: LUNR) sits at $14.81 versus a $29.50 consensus target, implying roughly 99% upside after the Lanteris acquisition transformed its business scale.
Planet Labs (NYSE: PL) trades at $18.12 against a $35.36 target and is down 24.28% over the past month despite posting a Q2 beat that surprised analysts.
BlackSky Technology (NYSE: BKSY) is the group’s worst monthly performer at -29.7%, trading at $20.50 versus a $38.42 consensus target, with all six covering analysts rating it Buy or Hold.
Rocket Lab carries by far the largest market cap, deepest backlog, and lowest execution binary of its peer group, giving it a structural advantage even as Neutron execution remains unproven.
The bull case sharpens materially if Neutron reaches the pad in Q4 2026 and achieves a clean first flight, which management said would flip standalone free cash flow positive within 18 to 24 months.
